INSMInsmed Incorporated
Price
-30%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, a flag to check, growing in the filings, the market undecided.
We are a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. Our commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. To complement our internal research and development, we also actively evaluate in-licensing and acquisition opportunities for commercial products, product candidates and technologies.
In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Insmed Incorporated (INSM) reported revenue of $425M in Q2 2026 (quarter ended Jun 30, 2026), up 296% from the same quarter a year earlier. That came with a gross margin of 84% and net loss of $13M. For the full year FY2025, revenue was $606M (+67% year on year) and net income −$1.28B. Its largest region in Q2 2026 was United States at $70M, 60% of the disclosed total, well ahead of Non Us at 40%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 5, 2026On October 5, 2026, Insmed Incorporated (the “Company”) announced that Sara Bonstein, the Company’s Chief Financial Officer, would be separating from the Company, effective October 30, 2026, and the Company has a search underway to identify a successor.Director or officer change · Form 8-K
- Aug 6, 2026Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- Jul 16, 2026Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients.Regulation FD disclosure · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $116.3MThe company’s own SEC segment disclosure.
- United States$70.2M60%
- Non Us$46.1M40%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Biotechnology
Ranks #38 of 196 by RyuScore